MarketCap
Facebook
X
TelegramQuarterly report 2023-Q4
added 02-12-2024
Nemaura Medical Cost of Revenue 2011-2026 | NMRD
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Nemaura Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.3 K | 344 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 344 K | 75.3 K | 210 K |
Quarterly Cost of Revenue Nemaura Medical
| 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2.97 K | 72.4 K | 72.4 K | - | 172 K | 172 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 172 K | 2.97 K | 98.5 K |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
EDAP TMS S.A.
EDAP
|
36 M | $ 3.42 | -2.43 % | $ 128 M |  France |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M |  USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 11.96 | -0.95 % | $ 1.62 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 9.14 | -2.56 % | $ 259 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 90.44 | 2.08 % | $ 12.2 B | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 36.34 | -1.09 % | $ 5.42 K | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 1.79 | -5.79 % | $ 1.09 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 9.29 | -0.21 % | $ 715 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 54.5 | 0.66 % | $ 1.6 B | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.0 | 0.34 % | $ 16.9 M | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 85.22 | -0.48 % | $ 2.96 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.7 | -1.54 % | $ 368 M | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.83 | -1.1 % | $ 69.7 M | USA |
 |
Medtronic PLC
MDT
|
11.6 B | $ 86.5 | 0.25 % | $ 111 B | USA |
 |
Myomo
MYO
|
14 M | $ 0.67 | -5.3 % | $ 28 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 167.2 | -2.72 % | $ 12.5 B | USA |
 |
Orthofix Medical
OFIX
|
256 M | $ 11.72 | -0.4 % | $ 464 M |  Curacao |
 |
AxoGen
AXGN
|
57.9 M | $ 30.54 | -6.43 % | $ 1.41 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 204.83 | 0.65 % | $ 14.4 B | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Sintx Technologies
SINT
|
557 K | $ 2.63 | 3.95 % | $ 7.29 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.0 | -3.27 % | $ 847 M | USA |
 |
Smith & Nephew plc
SNN
|
1.54 B | $ 31.7 | -2.85 % | $ 23.8 B |  Britain |
 |
Stryker Corporation
SYK
|
9.05 B | $ 331.21 | -0.33 % | $ 127 B | USA |
 |
Tactile Systems Technology
TCMD
|
79.4 M | $ 24.24 | -1.38 % | $ 554 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.6 | 1.68 % | $ 37.3 M | USA |
 |
TELA Bio
TELA
|
25.6 M | $ 0.68 | 7.69 % | $ 31.9 M | USA |
 |
TransMedics Group
TMDX
|
243 M | $ 107.12 | 2.21 % | $ 3.64 B | USA |
 |
Tandem Diabetes Care
TNDM
|
469 M | $ 18.93 | -1.28 % | $ 1.29 B | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.66 | -0.41 % | $ 346 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 61.25 | -2.14 % | $ 90.7 B | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 11.14 | 1.55 % | $ 1.67 B | USA |